LYKALABS.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:59):

Stats
Today's Volume	61 848.00
Average Volume	97 828.00
Market Cap	3.79B
EPS	INR0 ( 2024-02-08 )
Next earnings date	( INR0 ) 2024-05-20
Last Dividend	INR2.50 ( 1996-08-12 )
Next Dividend	INR0 ( N/A )
P/E	-93.09
ATR14	INR0.217 (0.19%)

Volume Correlation

Long: -0.14 (neutral)

Short: -0.67 (moderate negative)

Signal:(59.05) Neutral

Lyka Labs Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lyka Labs Limited Correlation - Currency/Commodity

-0.48
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.78
( moderate negative )

0.41
( neutral )

0.63
( weak )

Lyka Labs Limited Financials

Annual	2022
Revenue:	INR930.73M
Gross Profit:	INR555.18M (59.65 %)
EPS:	INR-4.57

FY	2022
Revenue:	INR930.73M
Gross Profit:	INR555.18M (59.65 %)
EPS:	INR-4.57

FY	2022
Revenue:	INR1.84B
Gross Profit:	INR1.30B (70.97 %)
EPS:	INR13.57

FY	2021
Revenue:	INR671.07M
Gross Profit:	INR291.40M (43.42 %)
EPS:	INR-4.07

Financial Reports:

No articles found.

Lyka Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lyka Labs Limited Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0.497 - No dividend growth expected in the near future

Information

First Dividend	INR2.50	1995-09-11
Last Dividend	INR2.50	1996-08-12
Next Dividend	INR0	N/A
Payout Date	1996-10-01
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	INR5.00	--
Avg. Dividend % Per Year	0.00%	--
Score	0.58	--
Div. Sustainability Score	0
Div.Growth Potential Score	0.497
Div. Directional Score	0.210	--

Next Divdend (Est)
(2024-07-22)

INR0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.58

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1995	INR0	0.00%
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
UBL.NS	Dividend Junior	2023-08-03	Annually	17	0.27%
POKARNA.NS	Dividend Junior	2023-09-11	Annually	9	0.19%
JMFINANCIL.NS	Dividend Junior	2023-05-19	Annually	18	1.09%
DIXON.NS	Dividend Knight	2023-09-22	Annually	7	0.04%
63MOONS.NS	Dividend Junior	2023-09-20	Annually	20	0.75%
SOUTHBANK.NS	Dividend Junior	2023-08-17	Sporadic	25	0.42%
MOLDTECH.NS	Dividend Knight	2023-09-18	Annually	9	1.62%
HEG.NS	Dividend Junior	2023-08-24	Annually	23	1.70%
BHARATRAS.NS	Dividend Junior	2023-09-06	Annually	17	0.01%
RAMCOCEM.NS	Dividend Junior	2023-08-02	Annually	23	0.21%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0336	1.500	-0.672	-1.007	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.125	1.500	-2.50	-3.75	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0.735	1.000	-0.839	-0.839	[3 - 30]
operatingCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
freeCashFlowPerShareTTM	8.01	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.614	1.000	3.11	3.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0464	1.000	-1.072	-1.072	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.0770

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-109.17	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.125	2.50	-1.606	-3.75	[0.1 - 1.5]
freeCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.225	1.500	-4.83	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.251	1.000	6.23	0	[0.1 - 0.5]
Total Score				0.497

Lyka Labs Limited

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.